: A new generation of ulcerative colitis drugs is in development. Will they be blockbusters for Lilly and Pfizer?

Read Time:7 Second

Pfizer’s promising ulcerative colitis treatment could generate $1.9 billion in sales by 2030. Lilly’s got a drug in development, too.

About Post Author

Happy

0 %

Sad

0 %

Excited

0 %

Sleepy

0 %

Angry

0 %

Surprise

0 %

This week’s aggressive Fed rate cut could provide some breathing space for distressed companies, notes one bankruptcy attorney.

Investors are mulling strategies beyond cash on expectations that interest rates will continue to fall after the Fed’s big rate...

The package-delivery giant said reduced demand for priority services and higher operating costs weighed on results.

Elliott Hill will replace John Donahoe as chief executive next month, following months of struggles for the athletic-wear giant.

It’s that time again: Investors will see option contracts tied to more than $5 trillion in tradeable stocks expire on...

Mortgage rates inched up even though the Federal Reserve cut interest rates. Experts explain why this is a short-lived phenomenon.